Agilent Technologies (A) to Release Quarterly Earnings on Monday

Agilent Technologies (NYSE:A) is anticipated to release its Q4 2025 results after the market closes on Monday, November 24th. Analysts expect the company to announce earnings of $1.59 per share and revenue of $1.8325 billion for the quarter. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS.Parties can find conference call details on the company’s upcoming Q4 2025 earningreport page for the latest details on the call scheduled for Monday, November 24, 2025 at 4:30 PM ET.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.37. The company had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.Agilent Technologies’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.32 earnings per share. On average, analysts expect Agilent Technologies to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Agilent Technologies Stock Performance

A stock opened at $146.90 on Monday. The company has a market capitalization of $41.65 billion, a P/E ratio of 34.48, a PEG ratio of 4.67 and a beta of 1.29. The business has a 50-day moving average price of $137.63 and a 200 day moving average price of $124.00. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. Agilent Technologies has a 1-year low of $96.43 and a 1-year high of $153.84.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 22nd. Stockholders of record on Tuesday, September 30th were issued a dividend of $0.248 per share. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.99 annualized dividend and a dividend yield of 0.7%. Agilent Technologies’s dividend payout ratio is 23.24%.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 12,490 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total transaction of $1,873,500.00. Following the transaction, the chief executive officer owned 33,448 shares in the company, valued at $5,017,200. This represents a 27.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Agilent Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of A. Fiduciary Trust Co increased its position in Agilent Technologies by 1.6% during the third quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company’s stock worth $633,000 after buying an additional 77 shares in the last quarter. Modern Wealth Management LLC grew its holdings in Agilent Technologies by 5.7% in the second quarter. Modern Wealth Management LLC now owns 2,889 shares of the medical research company’s stock worth $341,000 after purchasing an additional 157 shares during the period. Rehmann Capital Advisory Group lifted its stake in Agilent Technologies by 11.1% during the 3rd quarter. Rehmann Capital Advisory Group now owns 1,993 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 199 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in Agilent Technologies by 54.8% in the first quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company’s stock worth $70,000 after purchasing an additional 212 shares during the last quarter. Finally, Brighton Jones LLC raised its position in shares of Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock valued at $626,000 after purchasing an additional 270 shares during the period. 87.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price target on Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Rothschild Redb raised shares of Agilent Technologies to a “strong-buy” rating in a report on Wednesday, October 8th. Rothschild & Co Redburn started coverage on Agilent Technologies in a report on Wednesday, October 8th. They issued a “buy” rating and a $165.00 target price on the stock. Barclays increased their price target on Agilent Technologies from $125.00 to $150.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Finally, Wells Fargo & Company lifted their price objective on Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $149.62.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.